Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rintatolimod + FluMist
- Development stage
- Preclinical
- Lead developer
- AIM ImmunoTech
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
rintatolimod + FluMist is an investigational intranasal combination therapy being developed by AIM ImmunoTech (formerly Hemispherx Biopharma) for the prevention of influenza, including seasonal and avian strains. The combination consists of **rintatolimod** (Ampligen), a synthetic double-stranded RNA (dsRNA) molecule that acts as a selective **Toll-like receptor 3 (TLR3)** agonist, and **FluMist**, a live-attenuated influenza vaccine (LAIV) manufactured by AstraZeneca. In this formulation, rintatolimod serves as a mucosal adjuvant designed to enhance the innate and adaptive immune responses triggered by the vaccine. By activating TLR3 without inducing excessive inflammatory cytokines, rintatolimod aims to broaden the cross-reactivity of the vaccine-induced antibodies and T-cell responses, potentially providing better protection against drifted or emerging pandemic influenza strains, such as H5N1.
- Brand names
- AmpligenFluMist
- Other names
- rintatolimod + intranasal influenza vaccineAmpligen + FluMist combination
02
Targets
TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on rintatolimod + FluMist.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rintatolimod + FluMist.